Literature DB >> 6106389

Tardive dyskinesia: summary of a Task Force Report of the American Psychiatric Association. By the Task Force on Late Neurological Effects of Antipsychotic Drugs.

.   

Abstract

Abnormal movements associated with the prolonged use of antipsychotic drugs (tardive dyskinesia) occur in at least 10%-20% of the patients at risk; prevalence is higher among the elderly. The casue is unknown, but increased sensitivity to dopamine in the basal ganglia may contribute to the pathophysiology. Many treatments have been evaluated; none is satisfactory. While the problem is serious, an alarmist view is unwarranted, especially since many cases are detected early and improve spontaneously. The best approach currently is to use antipsychotic drugs thoughtfully for clear indications, the best supported of which, scientifically, is chronic schizophrenia. There is a search for new agents with much less adverse neurologic effect but with adequate antipsychotic efficacy. This article summarizes an APA Task Force Report.

Entities:  

Mesh:

Substances:

Year:  1980        PMID: 6106389     DOI: 10.1176/ajp.137.10.1163

Source DB:  PubMed          Journal:  Am J Psychiatry        ISSN: 0002-953X            Impact factor:   18.112


  24 in total

Review 1.  Past and present progress in the pharmacologic treatment of schizophrenia.

Authors:  John M Kane; Christoph U Correll
Journal:  J Clin Psychiatry       Date:  2010-09       Impact factor: 4.384

2.  Tardive Dyskinesia.

Authors: 
Journal:  Curr Treat Options Neurol       Date:  2000-05       Impact factor: 3.598

3.  Development of clinical methods for utilization review in psychiatric day treatment.

Authors:  K G Terkelsen; R H McCarthy; R L Munich; B E Hurley
Journal:  J Ment Health Adm       Date:  1994

Review 4.  Stiffness: a pathophysiologic approach to diagnosis and treatment.

Authors:  E L Siegler; L H Beck
Journal:  J Gen Intern Med       Date:  1989 Nov-Dec       Impact factor: 5.128

5.  Striatal dopamine D2 receptors in tardive dyskinesia: PET study.

Authors:  J Blin; J C Baron; H Cambon; A M Bonnet; B Dubois; C Loc'h; B Mazière; Y Agid
Journal:  J Neurol Neurosurg Psychiatry       Date:  1989-11       Impact factor: 10.154

Review 6.  Antipsychotic drugs. Clinical pharmacokinetics of potential candidates for plasma concentration monitoring.

Authors:  A E Balant-Gorgia; L Balant
Journal:  Clin Pharmacokinet       Date:  1987-08       Impact factor: 6.447

7.  Treatment schedule as a determinant of the development of tolerance to haloperidol.

Authors:  R J Carey; J DeVeaugh-Geiss
Journal:  Psychopharmacology (Berl)       Date:  1984       Impact factor: 4.530

Review 8.  Drug treatment of resistant schizophrenia. Limitations and recommendations.

Authors:  A E Farmer; A Blewett
Journal:  Drugs       Date:  1993-03       Impact factor: 9.546

9.  Supersensitivity psychosis in schizophrenic patients after sudden clozapine withdrawal.

Authors:  B Ekblom; K Eriksson; L H Lindström
Journal:  Psychopharmacology (Berl)       Date:  1984       Impact factor: 4.530

10.  Neuroleptic-induced striatal dopamine receptor supersensitivity in mice: relationship to dose and drug.

Authors:  J A Severson; H E Robinson; G M Simpson
Journal:  Psychopharmacology (Berl)       Date:  1984       Impact factor: 4.530

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.